PURPOSE: Anterior ischemic optic neuropathy (AION) is an important cause of acute vision loss in adults, and there is no effective treatment. We studied early changes following experimental AION and tested the benefit of a potential treatment. MATERIALS AND METHODS: We induced experimental AION in adult mice and tested the effects of short-term (daily for 3 days) and long-term (every other day for 3 weeks) αB-crystallin (αBC) treatment using histological and serial intracranial flash visual evoked potential recordings. RESULTS: One day after experimental AION, there was swelling at the optic nerve (ON) head and increased expression of αBC, a small heat shock protein important in ischemia and inflammation. This upregulation coincided with microglial and astrocytic activation. Our hypothesis was that αBC may be part of the endogenous protective mechanism against injury, thus we tested the effects of αBC on experimental AION. Daily intraveneous or intravitreal αBC injections did not improve visual evoked potential amplitude or latency at days 1-2. However, αBC treatment decreased swelling and dampened the microglial and astrocytic activation on day 3. Longer treatment with intravenous αBC led to acceleration of visual evoked potential latency over 3 weeks, without improving amplitude. This latency acceleration did not correlate with increased retinal ganglion cell survival but did correlate with complete rescue of the ON oligodendrocytes, which are important for myelination. CONCLUSIONS: We identified αBC as an early marker following experimental AION. Treatment with αBC enhanced this endogenous, post-ischemic response by decreasing microglial activation and promoting ON oligodendrocyte survival.
PURPOSE:Anterior ischemic optic neuropathy (AION) is an important cause of acute vision loss in adults, and there is no effective treatment. We studied early changes following experimental AION and tested the benefit of a potential treatment. MATERIALS AND METHODS: We induced experimental AION in adult mice and tested the effects of short-term (daily for 3 days) and long-term (every other day for 3 weeks) αB-crystallin (αBC) treatment using histological and serial intracranial flash visual evoked potential recordings. RESULTS: One day after experimental AION, there was swelling at the optic nerve (ON) head and increased expression of αBC, a small heat shock protein important in ischemia and inflammation. This upregulation coincided with microglial and astrocytic activation. Our hypothesis was that αBC may be part of the endogenous protective mechanism against injury, thus we tested the effects of αBC on experimental AION. Daily intraveneous or intravitreal αBC injections did not improve visual evoked potential amplitude or latency at days 1-2. However, αBC treatment decreased swelling and dampened the microglial and astrocytic activation on day 3. Longer treatment with intravenous αBC led to acceleration of visual evoked potential latency over 3 weeks, without improving amplitude. This latency acceleration did not correlate with increased retinal ganglion cell survival but did correlate with complete rescue of the ON oligodendrocytes, which are important for myelination. CONCLUSIONS: We identified αBC as an early marker following experimental AION. Treatment with αBC enhanced this endogenous, post-ischemic response by decreasing microglial activation and promoting ON oligodendrocyte survival.
Authors: Hirokazu Sakaguchi; Masaru Miyagi; Ruth M Darrow; John S Crabb; Joe G Hollyfield; Daniel T Organisciak; John W Crabb Journal: Exp Eye Res Date: 2003-01 Impact factor: 3.467
Authors: Farid Ahmed; Mario Torrado; Rina D Zinovieva; Vladimir V Senatorov; Graeme Wistow; Stanislav I Tomarev Journal: Invest Ophthalmol Vis Sci Date: 2004-09 Impact factor: 4.799
Authors: Steven L Bernstein; Yan Guo; Bernard J Slater; Adam Puche; Shalom E Kelman Journal: Invest Ophthalmol Vis Sci Date: 2007-05 Impact factor: 4.799
Authors: Celia S Chen; Mary A Johnson; Robert A Flower; Bernard J Slater; Neil R Miller; Steven L Bernstein Journal: Invest Ophthalmol Vis Sci Date: 2008-03-07 Impact factor: 4.799
Authors: Jonathan B Rothbard; Michael P Kurnellas; Sara Brownell; Chris M Adams; Leon Su; Robert C Axtell; Rong Chen; C Garrison Fathman; William H Robinson; Lawrence Steinman Journal: J Biol Chem Date: 2012-02-03 Impact factor: 5.157
Authors: Ram H Nagaraj; Rooban B Nahomi; Niklaus H Mueller; Cibin T Raghavan; David A Ammar; J Mark Petrash Journal: Biochim Biophys Acta Date: 2015-04-01
Authors: Jonathan B Rothbard; Michael P Kurnellas; Shalina S Ousman; Sara Brownell; Jesse J Rothbard; Lawrence Steinman Journal: Cold Spring Harb Perspect Med Date: 2019-07-01 Impact factor: 6.915
Authors: Michael P Kurnellas; Sara E Brownell; Leon Su; Andrey V Malkovskiy; Jayakumar Rajadas; Gregory Dolganov; Sidharth Chopra; Gary K Schoolnik; Raymond A Sobel; Jonathan Webster; Shalina S Ousman; Rachel A Becker; Lawrence Steinman; Jonathan B Rothbard Journal: J Biol Chem Date: 2012-09-06 Impact factor: 5.157